Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance

Hormone receptor-positive breast cancer accounts for around 75% of breast cancers. The estrogen receptor pathway promotes tumor progression and endocrine resistance. Recently, the cross-talk between the ER signaling pathway and cell cycle regulation has been identified. It is necessary to determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jing, Wen, Ti, Li, Zhi, Feng, Liang, Zhou, Lu, Yang, Zichang, Xu, Lu, Shi, Sha, Hou, Kezuo, Shen, Jiming, Han, Xu, Teng, Yuee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655217/
https://www.ncbi.nlm.nih.gov/pubmed/33098638
http://dx.doi.org/10.18632/aging.103966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655217/
https://www.ncbi.nlm.nih.gov/pubmed/33098638
http://dx.doi.org/10.18632/aging.103966

Ejemplares similares